Literature DB >> 18498242

Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with Type 1 diabetes.

M Loredana Marcovecchio1, Barry Widmer, David B Dunger, R Neil Dalton.   

Abstract

ADMA (asymmetric dimethylarginine), an endogenous inhibitor of nitric oxide synthase, is considered a major risk factor for cardiovascular disease and progression of renal disease. In the present study we aim to investigate the effect of acute variations in plasma glucose and insulin on plasma ADMA levels in young people with T1D (Type 1 diabetes). Fifteen young patients (ten males) with T1D, median age 18.3 (13.2-24.4) years, HbA(1c) (glycated haemoglobin) 9% (6.4-13.6%), underwent an overnight (18:00-08:00 hours) variable insulin infusion for euglycaemia, followed by a hyperinsulinaemic-euglycaemic clamp (08:00-12:00 hours). Blood samples were collected every 15 min for determination of ADMA, SDMA (symmetric dimethylarginine), valine, phenylalanine, arginine, creatinine and glucose. Insulin levels were assessed every 30 min. During the overnight period, glucose levels increased following the evening meal. In response to the protein intake there was a significant increase in ADMA, arginine, valine, phenylalanine and creatinine. For the remaining part of the night, glucose levels progressively decreased reaching 5 mmol/l by 04:00 hours. ADMA and SDMA did not change significantly. During the hyperinsulinaemic clamp, a significant fall in ADMA was observed, from 0.468+/-0.056 to 0.364+/-0.050 micromol/l (P<0.001). A significant fall was also found in SDMA, valine, phenylalanine, arginine and the ADMA/SDMA ratio (all P<0.001), but not in creatinine levels. No correlation was found between insulin sensitivity and ADMA. We conclude that acute changes in glycaemia do not significantly affect plasma ADMA levels whereas infusion of insulin significantly reduces ADMA, suggesting an important role for insulin in the regulation of this cardiovascular risk factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498242     DOI: 10.1042/CS20080079

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

1.  Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU).

Authors:  M Huemer; B Simma; D Mayr; D Möslinger; A Mühl; I Schmid; H Ulmer; O A Bodamer
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation.

Authors:  Naoko Sasaki; Yasuo Okumura; Ichiro Watanabe; Hiroaki Mano; Koichi Nagashima; Kazumasa Sonoda; Rikitake Kogawa; Kimie Ohkubo; Toshiko Nakai; Atsushi Hirayama
Journal:  J Interv Card Electrophysiol       Date:  2014-02-20       Impact factor: 1.900

3.  Enhancing eNOS activity with simultaneous inhibition of IKKβ restores vascular function in Ins2(Akita+/-) type-1 diabetic mice.

Authors:  Manickam Krishnan; Preethi Janardhanan; Linda Roman; Robert L Reddick; Mohan Natarajan; Rien van Haperen; Samy L Habib; Rini de Crom; Sumathy Mohan
Journal:  Lab Invest       Date:  2015-07-27       Impact factor: 5.662

Review 4.  Cellular ADMA: regulation and action.

Authors:  Tom Teerlink; Zaiming Luo; Fredrik Palm; Christopher S Wilcox
Journal:  Pharmacol Res       Date:  2009-08-12       Impact factor: 7.658

5.  Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control.

Authors:  Chiao-Po Hsu; Pai-Feng Hsu; Ming-Yi Chung; Shing-Jong Lin; Tse-Min Lu
Journal:  Cardiovasc Diabetol       Date:  2014-12-03       Impact factor: 9.951

Review 6.  Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis.

Authors:  Manuela Di Franco; Bruno Lucchino; Fabrizio Conti; Guido Valesini; Francesca Romana Spinelli
Journal:  Mediators Inflamm       Date:  2018-01-18       Impact factor: 4.711

7.  Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes.

Authors:  Thomas Forst; Andreas Pfützner; Frank Flacke; Alan Krasner; Cloth Hohberg; Eda Tarakci; Philip Pichotta; Senait Forst; Solomon Steiner
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

8.  Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study.

Authors:  Olga Kruszelnicka; Andrzej Surdacki; Alain Golay
Journal:  Cardiovasc Diabetol       Date:  2013-10-09       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.